

产品名称：**BP-1-102**

产品别名：**BP-1-102**

生物活性:				
Description	BP-1-102 is an orally available, small-molecule inhibitor of transcription factor Stat3, with an IC ₅₀ of 6.8 μM.			
IC ₅₀ & Target	STAT3			
	6.8 μM (IC ₅₀)			
In Vitro	BP-1-102 binds Stat3 with an affinity K _D of 504 nM. BP-1-102 inhibits Stat3 DNA-binding activity <i>in vitro</i> , with an IC ₅₀ value of 6.8±0.8 μM. It blocks Stat3-phospho-tyrosine peptide interactions and Stat3 activation at 4-6.8 μM, and selectively inhibits growth, survival, migration, and invasion of Stat3-dependent tumor cells. BP-1-102-mediated inhibition of aberrantly active Stat3 in tumor cells suppresses the expression of c-Myc, Cyclin D1, Bcl-xL, Survivin, VEGF, and Krüppel-like factor 8[1].			
In Vivo	Mice therapeutically given BP-1-102, an orally bioavailable compound targeting STAT3/NF-κB activation and cross-talk, exhibit reduced colon tumorigenesis and diminished expression of STAT3/NF-κB-activating cytokines in the neoplastic areas[2]. BP-1-102 is orally bioavailable and that the agent accumulates in tumor tissues at levels sufficient to inhibit aberrantly active Stat3 functions and inhibit tumor growth[1].			
Solvent&Solubility	In Vitro: DMSO : ≥ 33 mg/mL (52.67 mM) * "≥" means soluble, but saturation unknown.			
	<div>Preparing Stock Solutions</div>	<div>Solvent / Mass / Concentration</div>	1 mg	5 mg
		1 mM	1.5959 mL	7.9797 mL
		5 mM	0.3192 mL	1.5959 mL
		10 mM	0.1596 mL	0.7980 mL
	*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。 -80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。			
	In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶			
	1.请依序添加每种溶剂： 10% DMSO→40% PEG300 →5% Tween-80 → 45% saline Solubility: ≥ 2.5 mg/mL (3.99 mM); Clear solution 此方案可获得 ≥ 2.5 mg/mL (3.99 mM, 饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀 向上述体系中加入 50 μL Tween-80，混合均匀；然后继续加入 450 μL 生理盐水定容至 1 mL。			
	2.请依序添加每种溶剂： 10% DMSO →90% corn oil Solubility: ≥ 2.5 mg/mL (3.99 mM); Clear solution 此方案可获得 ≥ 2.5 mg/mL (3.99 mM, 饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的			

	<p>实验。</p> <p>以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 玉米油中，混合均匀。</p>
References	<p>[1]. Zhang X, et al. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. <i>Proc Natl Acad Sci U S A</i>. 2012 Jun 12;109(24):9623-8.</p> <p>[2]. De Simone V, et al. Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth. <i>Oncogene</i>. 2015 Jul;34(27):3493-503.</p>
实验参考：	
Cell Assay	<p>Proliferating cells in 6- or 96-well plates are treated once with 0-30 μM BP-1-102 for 24 h or with 10 μM BP-1-102 for up to 96 h. Viable cells are counted by trypan blue exclusion/phase-contrast microscopy or assessed by a cell proliferation kit[1].</p>
Animal Administration	<p>Mice: Athymic nude mice with established tumors are grouped and then given BP-1-102 (in 0.05% DMSO in water) at 1 or 3mg/kg (i.v.) every 2 or every 3 d or 3 mg/kg (oral gavage, 100 μL) every day for 15 or 20 d. Animals are monitored every day, and tumor sizes are measured with calipers and body weights are taken every 2 or 3 d. For each treatment group, the tumor volumes for each set of measurements are statistically analyzed in comparison with the control group using a paired T test[1].</p>
References	<p>[1]. Zhang X, et al. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. <i>Proc Natl Acad Sci U S A</i>. 2012 Jun 12;109(24):9623-8.</p> <p>[2]. De Simone V, et al. Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth. <i>Oncogene</i>. 2015 Jul;34(27):3493-503.</p>

源叶生物